Nestle SA
37 articles about Nestle SA
-
Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres’s investigational oral microbiome treatment for recurrent Clostridioides difficile infections.
-
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
10/13/2020
Société des Produits Nestlé S.A. announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc., to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc., other than any Shares held by Nestlé and its affiliates, for a price of USD 34.50 per Share
-
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
9/14/2020
Société des Produits Nestlé S.A. announced that its wholly-owned subsidiary, SPN Merger Sub, Inc., is commencing a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc. today for a price of USD 34.50 per share, net to the seller in cash, without interest and subject to any withholding taxes.
-
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
8/31/2020
Sociétés des Produits Nestlé S.A., part of Nestlé Health Science, to acquire Aimmune for $34.50 per share in cash, representing a total equity value of $2.6 Billion and a 174% premium to Aimmune’s closing price on August 28, 2020
-
Nestlé Increases Stake in Aimmune as Company Eyes Filing for FDA Approval of Peanut Allergy Medicine
11/13/2018
As California-based Aimmune prepares to seek regulatory approval for its peanut allergy treatment, AR101, Nestlé Health Science has increased its financial stake in the food allergy prevention-focused company with another $98 million investment. -
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
-
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It
4/13/2018
Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it. -
Nestlé and Nuritas to Work Together on Discovery of Food-Derived Bioactive Peptides Through Artificial Intelligence
2/8/2018
Nestle and Nuritas have entered into a collaboration aiming at discovering bioactive peptide networks within specific target areas of significant value.
-
Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.
-
Codexis, Inc. And Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership
10/13/2017
-
Nestle's Galderma Laboratories to Slash Up to 450 Jobs at R&D Center
9/21/2017
-
Nestle SA Just Snatched Up Former Allergan Exec for Health Push
10/13/2016
-
Incoming Nestle SA CEO Wants to Steer Firm Down New Health Path
9/30/2016
-
Nestle SA to Buy British Medtech Phagenesis in Stages
9/1/2016
-
Nestle SA Extends Pharma Push by Contributing to Enterome's $16.5 Million Funding Round
4/20/2016
-
Medidata Solutions, Inc. And Nestle SA Partner On Mobile Health Study To Gauge Impact Of Nutrition Combined With Physical Activity In Healthy Aging Adults
3/10/2016
-
Nestle SA Pays $42.5 Million for Stake in Pronutria Biosciences
2/23/2016
-
Nestle SA Advances Further into Medicine with Planned Alzheimer's Test
9/23/2015
-
Nestle SA to Base New R&D Unit in Cambridge, Stays Mysterious About Details
5/12/2015
-
White-Hot Flagship Ventures Inks Deals With AstraZeneca PLC, Bayer CropScience AG and Nestle SA As VC Roars
5/5/2015